Skip to main content
Erschienen in: AIDS and Behavior 6/2020

18.12.2019 | Original Paper

Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study

verfasst von: Sean T. Allen, Allison O’Rourke, Rebecca Hamilton White, Katherine C. Smith, Brian Weir, Gregory M. Lucas, Susan G. Sherman, Suzanne M. Grieb

Erschienen in: AIDS and Behavior | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

The opioid crisis has increased risks for injection drug use-associated HIV outbreaks in rural communities throughout the United States. Existing research has examined pre-exposure prophylaxis (PrEP) utilization among people who inject drugs (PWID); however, no studies have been conducted to explore barriers and facilitators of PrEP use among rural PWID in Appalachia. We conducted qualitative interviews with PWID (n = 48) in two rural counties in West Virginia to explore barriers and facilitators of PrEP use. Among our participants, the majority (68.8%) had never heard of PrEP. Upon learning about PrEP, most participants expressed willingness to use it. Rural PWID described several factors that may impede PrEP utilization (e.g., housing instability, forgetting to take PrEP). Participants also identified practical strategies to support sustained PrEP utilization, such as integrating PrEP services into venues PWID access. This research provides important insights into the barriers and facilitators of PrEP utilization among rural PWID.
Literatur
3.
Zurück zum Zitat Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. 2015;64(26):719–25.PubMedPubMedCentral Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. 2015;64(26):719–25.PubMedPubMedCentral
4.
Zurück zum Zitat Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.PubMedPubMedCentralCrossRef Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323–31.PubMedPubMedCentralCrossRef Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323–31.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, et al. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16(1):33.PubMedPubMedCentralCrossRef Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, et al. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16(1):33.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Havens JR, Oser CB, Leukefeld CG. Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care. 2011;23(5):638–45.PubMedPubMedCentralCrossRef Havens JR, Oser CB, Leukefeld CG. Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care. 2011;23(5):638–45.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17(5):558–65.PubMedCrossRef Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17(5):558–65.PubMedCrossRef
9.
Zurück zum Zitat Crosby RA, Yarber WL, DiClemente RJ, Wingood GM, Meyerson B. HIV-associated histories, perceptions, and practices among low-income African American women: does rural residence matter? Am J Public Health. 2002;92(4):655–9.PubMedPubMedCentralCrossRef Crosby RA, Yarber WL, DiClemente RJ, Wingood GM, Meyerson B. HIV-associated histories, perceptions, and practices among low-income African American women: does rural residence matter? Am J Public Health. 2002;92(4):655–9.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Gamm LD. Mental health and substance abuse services among rural minorities. J Rural Health. 2004;20(3):206–9.PubMedCrossRef Gamm LD. Mental health and substance abuse services among rural minorities. J Rural Health. 2004;20(3):206–9.PubMedCrossRef
11.
Zurück zum Zitat Sung H-E, Mahoney AM, Mellow J. Substance abuse treatment gap among adult parolees: prevalence, correlates, and barriers. Crim Justice Rev. 2011;36(1):40–57.CrossRef Sung H-E, Mahoney AM, Mellow J. Substance abuse treatment gap among adult parolees: prevalence, correlates, and barriers. Crim Justice Rev. 2011;36(1):40–57.CrossRef
12.
Zurück zum Zitat Sexton RL, Carlson RG, Leukefeld CG, Booth BM. Barriers to formal drug abuse treatment in the rural south: a preliminary ethnographic assessment. J Psychoact Drugs. 2008;40(2):121–9.CrossRef Sexton RL, Carlson RG, Leukefeld CG, Booth BM. Barriers to formal drug abuse treatment in the rural south: a preliminary ethnographic assessment. J Psychoact Drugs. 2008;40(2):121–9.CrossRef
13.
Zurück zum Zitat Staton-Tindall M, Webster JM, Oser CB, Havens JR, Leukefeld CG. Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women. Soc Work Public Health. 2015;30(4):385–96.PubMedPubMedCentralCrossRef Staton-Tindall M, Webster JM, Oser CB, Havens JR, Leukefeld CG. Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women. Soc Work Public Health. 2015;30(4):385–96.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef
19.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedPubMedCentralCrossRef Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Alpren C, Dawson EL, John B, Cranston K, Panneer N, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.PubMedPubMedCentralCrossRef Alpren C, Dawson EL, John B, Cranston K, Panneer N, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(22):2203–13.CrossRef US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(22):2203–13.CrossRef
25.
26.
Zurück zum Zitat Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.PubMedPubMedCentralCrossRef Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Walters SM, Rivera AV, Starbuck L, Reilly KH, Boldon N, Anderson BJ, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S383–91.PubMedCrossRef Walters SM, Rivera AV, Starbuck L, Reilly KH, Boldon N, Anderson BJ, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S383–91.PubMedCrossRef
28.
Zurück zum Zitat Kuo I, Olsen H, Patrick R, Phillips G 2nd, Magnus M, Opoku J, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.PubMedCrossRef Kuo I, Olsen H, Patrick R, Phillips G 2nd, Magnus M, Opoku J, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.PubMedCrossRef
29.
Zurück zum Zitat Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.PubMedCrossRef Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.PubMedCrossRef
30.
Zurück zum Zitat Escudero DJ, Kerr T, Wood E, Nguyen P, Lurie MN, Sued O, et al. Acceptability of HIV pre-exposure prophylaxis (PREP) among people who inject drugs (PWID) in a Canadian Setting. AIDS Behav. 2015;19(5):752–7.PubMedPubMedCentralCrossRef Escudero DJ, Kerr T, Wood E, Nguyen P, Lurie MN, Sued O, et al. Acceptability of HIV pre-exposure prophylaxis (PREP) among people who inject drugs (PWID) in a Canadian Setting. AIDS Behav. 2015;19(5):752–7.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–91.PubMedPubMedCentralCrossRef Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–91.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Mayer KH, Chan PA, Patel RR, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr. 2018;77(2):119–27.PubMedPubMedCentralCrossRef Mayer KH, Chan PA, Patel RR, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr. 2018;77(2):119–27.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14(1):231.PubMedPubMedCentralCrossRef Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14(1):231.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Ojikutu BO, Bogart LM, Higgins-Biddle M, Dale SK, Allen W, Dominique T, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav. 2018;22(11):3576–87.PubMedPubMedCentralCrossRef Ojikutu BO, Bogart LM, Higgins-Biddle M, Dale SK, Allen W, Dominique T, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav. 2018;22(11):3576–87.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Rice WS, Stringer KL, Sohail M, Crockett KB, Atkins GC, Kudroff K, et al. Accessing pre-exposure prophylaxis (PrEP): Perceptions of Current and Potential PrEP Users in Birmingham, Alabama. AIDS Behav. 2019;23:2966–79.PubMedCrossRefPubMedCentral Rice WS, Stringer KL, Sohail M, Crockett KB, Atkins GC, Kudroff K, et al. Accessing pre-exposure prophylaxis (PrEP): Perceptions of Current and Potential PrEP Users in Birmingham, Alabama. AIDS Behav. 2019;23:2966–79.PubMedCrossRefPubMedCentral
36.
Zurück zum Zitat Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.PubMedPubMedCentralCrossRef Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Bazzi AR, Biancarelli DL, Childs E, Drainoni ML, Edeza A, Salhaney P, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018;32(12):529–37.PubMedPubMedCentralCrossRef Bazzi AR, Biancarelli DL, Childs E, Drainoni ML, Edeza A, Salhaney P, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018;32(12):529–37.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat US Census Bureau. 2010 Census Urban and Rural Classification and Urban Area Criteria. US Census Bureau. 2010 Census Urban and Rural Classification and Urban Area Criteria.
39.
Zurück zum Zitat Bernard HR, Wutich A, Ryan GW. Analyzing qualitative data: systematic approaches. Thousand oaks: SAGE; 2016. Bernard HR, Wutich A, Ryan GW. Analyzing qualitative data: systematic approaches. Thousand oaks: SAGE; 2016.
40.
Zurück zum Zitat Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.CrossRef Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.CrossRef
41.
Zurück zum Zitat Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37–46.CrossRef Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37–46.CrossRef
43.
Zurück zum Zitat Allen ST, O’Rourke A, White RH, Schneider KE, Kilkenny M, Sherman SG. Estimating the number of people who inject drugs in a rural county in Appalachia. Am J Public Health. 2019;109(3):445–50.PubMedPubMedCentralCrossRef Allen ST, O’Rourke A, White RH, Schneider KE, Kilkenny M, Sherman SG. Estimating the number of people who inject drugs in a rural county in Appalachia. Am J Public Health. 2019;109(3):445–50.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.PubMedPubMedCentralCrossRef Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Calabrese SK, Earnshaw VA, Underhill K, et al. Prevention paradox: medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. J Int AIDS Soc. 2018;21(6):e25147.PubMedPubMedCentralCrossRef Calabrese SK, Earnshaw VA, Underhill K, et al. Prevention paradox: medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. J Int AIDS Soc. 2018;21(6):e25147.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016;28(9):1154–8.PubMedPubMedCentralCrossRef Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016;28(9):1154–8.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef
48.
Zurück zum Zitat Canary L, Hariri S, Campbell C, Young R, Whitcomb J, Kaufman H, et al. Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States. Clin Infect Dis. 2017;65(3):514–7.PubMedCrossRef Canary L, Hariri S, Campbell C, Young R, Whitcomb J, Kaufman H, et al. Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States. Clin Infect Dis. 2017;65(3):514–7.PubMedCrossRef
49.
Zurück zum Zitat Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR. 2015;64(48):1337–41.PubMed Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR. 2015;64(48):1337–41.PubMed
Metadaten
Titel
Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study
verfasst von
Sean T. Allen
Allison O’Rourke
Rebecca Hamilton White
Katherine C. Smith
Brian Weir
Gregory M. Lucas
Susan G. Sherman
Suzanne M. Grieb
Publikationsdatum
18.12.2019
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 6/2020
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02767-3

Weitere Artikel der Ausgabe 6/2020

AIDS and Behavior 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.